Related Experiment Video

Updated: Dec 17, 2025

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

3.0K

E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease

Kikkie Poels1, Winnie G Vos1, Esther Lutgens1,2,3

  • 1Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, Netherlands.

Frontiers in Cardiovascular Medicine
|June 26, 2020
PubMed

Insights

Targeting T-cell activation via E3 ubiquitin ligases like Cbl-B, Itch, and GRAIL offers a promising strategy to combat residual inflammation in atherosclerosis. These proteins act as natural brakes on T-cell activity, crucial for cardiovascular health.

Area of Science:

  • Immunology
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Chronic low-grade inflammation is a key driver of atherosclerosis.
  • Despite optimal treatment, residual inflammatory risk persists in one-third of patients with atherosclerotic cardiovascular disease.
  • T-cells are prevalent in atherosclerotic lesions, making their modulation a potential therapeutic target.

Purpose of the Study:

  • To review recent insights into the role of specific E3 ubiquitin ligases in atherosclerosis.
  • To explore the therapeutic potential of Cbl-B, Itch, and GRAIL in cardiovascular medicine.
  • To highlight novel anti-inflammatory strategies for residual inflammatory risk.

Main Methods:

  • Review of current scientific literature on T-cell activation and E3 ubiquitin ligases.
  • Analysis of the function of Cbl-B, Itch, and GRAIL in the context of atherosclerosis.
  • Exploration of therapeutic implications for cardiovascular disease.

Main Results:

  • E3 ubiquitin ligases, including Cbl-B, Itch, and GRAIL, act as natural regulators of T-cell activation.
  • These ligases play a significant role in the inflammatory processes underlying atherosclerosis.
  • Modulating these ligases presents a potential therapeutic avenue.

Conclusions:

  • Targeting E3 ubiquitin ligases offers a novel strategy to address residual inflammatory risk in atherosclerosis.
  • Understanding the role of Cbl-B, Itch, and GRAIL in T-cell activation is critical for developing new cardiovascular therapies.
  • Further research into these ligases could lead to innovative treatments for atherosclerotic cardiovascular disease.

Keywords:
Cbl-BE3 ubiquitin ligasesGRAILItchatherosclerosisinflammation

More Related Videos

In Vitro Analysis of E3 Ubiquitin Ligase Function06:06

In Vitro Analysis of E3 Ubiquitin Ligase Function

Published on: May 14, 2021

5.9K
Functional Characterization of RING-Type E3 Ubiquitin Ligases In Vitro and In Planta10:27

Functional Characterization of RING-Type E3 Ubiquitin Ligases In Vitro and In Planta

Published on: December 5, 2019

9.2K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
258
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.5K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
622
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
109